Profession

Blood product trial sparks informed consent debate

The FDA allows informed consent to be waived in emergency situations if other treatment is unavailable or unsatisfactory.

By Andis Robeznieks — Posted Dec. 6, 2004

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

A test for a new blood substitute has created tension between groups seeking to save lives and those looking to preserve research ethics.

While some investigators hail PolyHeme, an oxygen-carrying liquid produced by Evanston, Ill.-based Northfield Laboratories Inc., as a potential lifesaver, others say clinical trials for the product -- which include waiving test subjects' informed consent -- could set a precedent for future abuses of the Food and Drug Administration's guidelines, which allow such waivers in life-threatening situations.

The FDA did approve the protocol for the trial but would not discuss the controversy because of its policy of avoiding comment on studies in progress. AMA policy allows waiving informed consent for emergency medicine research if eight conditions are met, including informing a community that the research is taking place.

The trial involves giving patients in hemorrhagic shock PolyHeme instead of saline at the scene of injury or during transport to the hospital.

Some bioethicists are concerned because the trial can go on for hours after the patient has been admitted to a hospital. They argue that the main reason for the waiver, that satisfactory treatment is not available, is no longer being met once patients are admitted and have access to blood.

"The issue is whether this study meets the letter and the spirit of the regulations," said Arthur R. Derse, MD, clinical professor of emergency medicine and director of medical and legal affairs for the Medical College of Wisconsin's Center for Bioethics.

Nancy M.P. King, professor of social medicine at the University of North Carolina in Chapel Hill, said this test could lead to granting more waivers with less justification.

But a co-investigator of the study, Mark E. Cichon, DO, director of emergency medical services at Loyola University Medical Center in Maywood, Ill., said that even if blood is available, consent might not be possible because of the subject's mental status.

"When you do informed consent, it's not simply asking for permission, it's a discussion and a dynamic process," he said.

Northfield issued a Nov. 18 statement saying the FDA and the review boards at 16 medical institutions had approved the research protocol. Two IRBs have not.

Back to top


External links

AMA policy on the waiver of informed consent for research in emergency situations (link)

Northfield Laboratories' blood substitute PolyHeme (link)

PolyHeme Blood Substitute Trauma Trial at Loyola University Health System (link)

Back to top


ADVERTISEMENT

ADVERTISE HERE


Featured
Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story


Read story

Goodbye

American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story


Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story


Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story


Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story


Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story


Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story


Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn